BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27583930)

  • 1. Bevacizumab with preoperative chemotherapy versus preoperative chemotherapy alone for colorectal cancer liver metastases: a retrospective cohort study.
    Lu ZH; Peng JH; Wang FL; Yuan YF; Jiang W; Li YH; Wu XJ; Chen G; Ding PR; Li LR; Kong LH; Lin JZ; Zhang RX; Wan DS; Pan ZZ
    Medicine (Baltimore); 2016 Aug; 95(35):e4767. PubMed ID: 27583930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
    Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
    Umehara M; Umehara Y; Takahashi K; Murata A; Nishikawa S; Tokura T; Matsuzaka M; Tanaka R; Morita T
    Anticancer Res; 2016 Apr; 36(4):1949-54. PubMed ID: 27069185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
    Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
    Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.
    Jordan F; Grundmann N; Schenkirsch G; Märkl B; Messmann H; Anthuber M; Schmid C; Trepel M
    Anticancer Res; 2018 Sep; 38(9):5539-5546. PubMed ID: 30194214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
    Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
    Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
    Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
    Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.
    Basso M; Dadduzio V; Ardito F; Lombardi P; Strippoli A; Vellone M; Orlandi A; Rossi S; Cerchiaro E; Cassano A; Giuliante F; Barone C
    Medicine (Baltimore); 2016 May; 95(20):e3722. PubMed ID: 27196492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience.
    Cvetanovic A; Vrbic S; Filipovic S; Pejcic I; Milenkovic D; Milenkovic N; Zivkovic N
    J BUON; 2013; 18(3):641-6. PubMed ID: 24065477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Specific treatment situations in metastatic colorectal cancer].
    Arnold D; Schmoll HJ; Lang H; Knoefel WT; Ridwelski K; Trarbach T; Staib L; Kirchner T; Geissler M; Seufferlein T; Amthauer H; Riess H; Schlitt HJ; Piso P
    Onkologie; 2010; 33 Suppl 4():8-18. PubMed ID: 20431307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study.
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Clin Colorectal Cancer; 2016 Dec; 15(4):e165-e174. PubMed ID: 27256668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
    Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
    Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
    Blazer DG; Kishi Y; Maru DM; Kopetz S; Chun YS; Overman MJ; Fogelman D; Eng C; Chang DZ; Wang H; Zorzi D; Ribero D; Ellis LM; Glover KY; Wolff RA; Curley SA; Abdalla EK; Vauthey JN
    J Clin Oncol; 2008 Nov; 26(33):5344-51. PubMed ID: 18936472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.